Search

Researchers at Wenzhou Medical University in Zhejiang, China, have developed a dual-enzyme-instructed peptide self-assembly platform that utilizes camptothecin and capsaicin to enhance immunogenic cell death and stimulate systemic adaptive immunity for tumor rejection. This innovative approach synergizes two distinct apoptosis pathways to increase tumor immunogenicity, elicit T-cell-based immunity, and suppress both primary and distant tumors. The study, published in ACS Nano, demonstrates the potential of combining low ICD-stimulating chemotherapeutic drugs with peptide self-assembly to boost cancer immunotherapy. [Extracted from the article]

Researchers from Wenzhou Medical University in Zhejiang, China, have conducted a study on colon cancer cells with KRAS mutations to investigate the role of YY1 in mediating resistance to cetuximab therapy. The study found that YY1 expression was correlated with cetuximab resistance in KRAS mutant colorectal cancer tissues and cell lines. Silencing YY1 in resistant cells re-sensitized them to cetuximab, while overexpressing YY1 in sensitive cells enhanced resistance. The research concluded that YY1 plays a role in mediating resistance of KRAS mutant colorectal cancer cells to cetuximab therapy. [Extracted from the article]

A study conducted at Hangzhou Cancer Hospital in Zhejiang, China, explored the systemic immune-inflammation index (SII) as a prognostic factor for cancer patients undergoing immunotherapy. The research found that a higher SII level was associated with lower objective response rates, worse disease control rates, shorter overall survival, and unfavorable progression-free survival. The study suggests that a high SII level could serve as a non-invasive biomarker for predicting poor tumor response and adverse prognosis in advanced cancer patients receiving immunotherapy. [Extracted from the article]

Researchers from Zhejiang University in the People's Republic of China have developed a Sequential Release HydroLipo System (SRHLS) for treating Glioblastoma (GBM), a challenging form of cancer. The SRHLS combines hydrogels and nanoparticles to release decitabine and STING agonists, correcting signaling dysfunction and enhancing antitumor immunity. In vitro and in vivo experiments showed that the SRHLS effectively reshaped the tumor microenvironment and inhibited tumor growth, recurrence, and metastasis, suggesting it as a promising therapeutic strategy for GBM. [Extracted from the article]

Researchers from Wenzhou Medical University in Zhejiang, China, conducted a study on gastric cancer, focusing on the relationship between lysosomes, senescence, and prognosis. They identified two subtypes of gastric cancer, Cluster 1 and Cluster 2, with distinct molecular features and survival outcomes. The study also highlighted the potential of the MMP12 gene as a protective factor in gastric cancer cells, suggesting its relevance for targeted therapies and immunotherapies. This research provides valuable insights into predicting the prognosis of gastric cancer patients based on lysosome and senescence states. [Extracted from the article]

Researchers from Zhejiang Cancer Hospital conducted a study on metastatic gastric cancer, focusing on the link between ferroptosis, disease progression, and immunotherapy response. The study involved in-depth single-cell transcriptome and immune profiling of 68 paired primary metastatic tumors, revealing alterations in cancer cells and their microenvironment during metastatic progression. The research suggests that targeting ferroptosis defense in combination with chimeric antigen receptor T-cell therapy could be a novel therapeutic strategy with significant clinical implications. The study was published in Gastroenterology and was funded by various organizations including the National Institutes of Health (NIH) in the USA. [Extracted from the article]

Researchers at Wenzhou Medical University in Zhejiang, China, have explored the potential of pyroptosis-inducing biomaterials in antitumor immunotherapy. Pyroptosis, a form of cell death, has shown promise in overcoming immunosuppression and reactivating antitumor immunity. The study highlights the complex biological mechanisms of pyroptosis and the design options for biomaterials targeting gasdermin proteins to induce pyroptosis effectively. This research lays the groundwork for the development of pyroptosis-inducing biomaterials for future clinical applications in cancer treatment. [Extracted from the article]

A study conducted at Westlake University in Zhejiang, China, focused on the molecular mechanisms of Mono (2-ethylhexyl) phthalate (MEHP) in inducing lung adenocarcinoma (LUAD). The research utilized network toxicology, functional analyses, and molecular docking to identify core proteins targeted by MEHP and their impact on cancer and immune pathways. The study offers new insights into the toxicity of MEHP and potential targets for cancer prevention and treatment, providing a novel approach to evaluating the safety of plasticizers. The findings have been peer-reviewed and published in Bioorganic Chemistry. [Extracted from the article]

Researchers from Hangzhou Normal University in Zhejiang, China, have conducted a study on the role of gamma delta T cells in colorectal cancer (CRC). The research highlights the potential of immunotherapy, particularly in combination with chemotherapy, for treating CRC. The study emphasizes the unique characteristics of gamma delta T cells in targeting tumor cells and discusses the implications for developing more effective and less toxic immunotherapy-based anticancer drugs. This peer-reviewed research provides valuable insights into the complex interplay between immune cells, the tumor microenvironment, and cancer progression in CRC. [Extracted from the article]

Recent research from Shaoxing University in Zhejiang, China, highlights the use of polydopamine nanoparticles in synergistic photothermal immunotherapy for triple-negative breast cancer (TNBC). The study focuses on the development of PDA(R837) nanoformulations, which effectively induce immunogenic cell death and M1 phenotype macrophage polarization, leading to enhanced antitumor efficacy. The research suggests that these nanoformulations have promising clinical translational application prospects for cancer treatment. [Extracted from the article]

Researchers at Zhejiang University in China have conducted a study to determine alternative markers for plasma cell (PC) detection in multiple myeloma (MM) patients undergoing daratumumab therapy. They evaluated the suitability of CD229, CD269, and interferon regulatory factor (IRF-4) for distinguishing PCs from other hematopoietic cells and found that IRF-4 is a promising marker for PC identification in minimal residual disease (MRD) assessment of MM patients undergoing anti-CD38 therapy. The study concluded that IRF-4 expression is not affected by daratumumab treatment and can accurately identify normal PCs, aberrant PCs, and a combination of both in MRD assessment. [Extracted from the article]

A recent report from Zhuji People's Hospital in Zhejiang, China, discusses the treatment experience of a rare subtype of renal cancer called mucinous tubular and spindle cell carcinoma (MTSCC). The patient underwent surgery but experienced early recurrence and extensive retroperitoneal metastasis. The report highlights the challenges in treating metastatic MTSCC due to its rarity and lack of standardized treatment and follow-up strategies. The research suggests that aggressive surgical treatment combined with molecular targeted or immunotherapy may still be recommended, even in cases of distant metastasis. [Extracted from the article]

A recent study conducted by investigators at Hangzhou Normal University in Zhejiang, China, explores the use of metal-based nanoparticles to enhance cancer immunotherapy. The study focuses on the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, which plays a crucial role in the body's immune response to tumors. Metal-based nanomaterials show promise in activating this pathway and improving cancer immunotherapy. The research provides a comprehensive overview of how these nanoparticles affect the cGAS-STING pathway and discusses their potential uses in cancer treatment. [Extracted from the article]

A recent study conducted at Zhejiang Hospital in China explored a potential therapeutic strategy for B-cell lymphoma. The study focused on combining a histone deacetylase inhibitor (romidepsin) with PD-1 blockade (BMS-1) in a mouse model of B-cell lymphoma. The results showed that the combined treatment of romidepsin and BMS-1 synergistically inhibited the growth of B-cell lymphoma and triggered apoptosis. Additionally, the treatment activated tumor-infiltrating lymphocytes, particularly CD3+CD4+ and CD3+CD8+ T cells. The study suggests that the combination of HDAC inhibition and PD-1 blockade could be a promising approach for treating B-cell lymphoma and enhancing antitumor immunity. [Extracted from the article]

A recent study conducted by researchers at Zhejiang University in China explored the molecular mechanism controlling immune infiltration in lung adenocarcinoma (LUAD) cells. The study found that high expression of the HES6 gene promoted CD8+ T-cell infiltration and enhanced T-cell killing ability through oxidative phosphorylation. On the other hand, E2F1 negatively regulated HES6 by oxidative phosphorylation, suppressing CD8+ T-cell immune infiltration. Silencing HES6 was found to repress tumor cell immune evasion. The findings of this study contribute to a better understanding of the mechanisms regulating immune infiltration in LUAD. [Extracted from the article]

A recent study conducted by investigators from Zhejiang University in China explored the potential therapeutic effects of glycyrrhizic acid (GA), a bioactive ingredient found in licorice, on autoimmune hepatitis (AIH). The researchers found that GA intervention significantly reduced liver inflammation in mice with acute liver injury induced by Concanavalin A. Through various analyses, including CyTOF, multiplex immunofluorescence, and single-cell RNA sequencing, the study revealed that GA regulated the function of monocyte-derived macrophages (MoMFs) and shaped the immune microenvironment. These findings provide insights into the mechanism of action of GA and suggest potential avenues for AIH treatment and the development of immunotherapies centered around MoMFs. [Extracted from the article]

A recent report from Zhejiang University in China discusses the potential of stimulator of interferon genes (STING)-activating small molecular therapeutics for cancer immunotherapy. The report highlights the limitations and challenges of current immunotherapy treatments and emphasizes the need for new therapeutic molecules to improve clinical outcomes. The researchers review the development of STING-activating therapeutics, including cyclic dinucleotides (CDNs) and non-CDN STING agonists, and discuss their potential in triggering an innate immune response. The report concludes by discussing the limitations and challenges of these agents in clinical translation. [Extracted from the article]

A case report from Zhuji People's Hospital in Zhejiang, China, discusses the use of a combination of anlotinib and toripalimab as a potential treatment for advanced biliary tract cancer (BTC) patients with high Eastern Cooperative Oncology Group (ECOG) performance status. The report describes the case of a 67-year-old Chinese male with BTC who experienced a rapid decline in performance status. After receiving oral anlotinib and toripalimab, the patient achieved 17 months of progression-free survival (PFS) and another 11 months of PFS after developing solitary lung metastasis. The researchers conclude that anlotinib plus toripalimab may be an effective treatment option for advanced BTC patients with high ECOG performance status. [Extracted from the article]

A recent study conducted at Zhejiang University in China explores the use of anti-PD-1/PD-L1 immunotherapy in the conversion treatment of locally advanced hepatocellular carcinoma (HCC), a type of liver cancer. The research suggests that conversion treatment, which combines PD-1/PD-L1 inhibitors with locoregional therapy, can improve outcomes for patients with unresectable locally advanced HCC. The study concludes that PD-1/PD-L1 immunotherapy has the potential to be widely used in the conversion treatment of this type of liver cancer. The research has been peer-reviewed and published in Clinical and Experimental Medicine. [Extracted from the article]

A recent study conducted by researchers at Zhejiang University in China has shed light on the immune characteristics of colorectal cancer (CRC) tumors. The study found that CRC tumors can be classified as either "hot" or "cold" based on the presence of immune cell infiltration in the tumor microenvironment, which affects the efficacy of immunotherapy. The researchers developed an eight-gene signature prognostic risk model that can serve as an independent prognostic indicator for patients with stage II CRC. The study provides valuable insights into the immune characteristics of CRC tumors and offers a potential tool for predicting patient outcomes. [Extracted from the article]

A recent report from Zhejiang University in China discusses the prognosis and immune microenvironment of HER2-positive uterine serous carcinoma (USC). The study used immunohistochemistry and fluorescence in situ hybridization to investigate HER2 expression and amplification, PD-L1 expression, and tumor infiltration lymphocytes (TIL) in 77 USC cases. The researchers found that HER2 amplification was associated with poor overall and progression-free survival in USC, but also showed potential for an active immune microenvironment. The findings suggest the possibility of combining anti-HER2 therapy with immunotherapy for HER2-positive USC in the future. [Extracted from the article]

A recent study from Zhejiang, People's Republic of China, explores the potential of human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2) as an immune checkpoint for cancer immunotherapy. HHLA2 is a co-signaling molecule that is aberrantly expressed in various human cancers and interacts with two distinct receptors, TMIGD2 and KIR3DL3, to deliver co-stimulatory and inhibitory signals to immune cells. Therapeutic strategies targeting HHLA2 are being investigated in early clinical trials, and there is potential for combining HHLA2-targeted therapies with other immunotherapies to enhance antitumor activity. This research has been peer-reviewed and published in the Journal of Leukocyte Biology. [Extracted from the article]

A report from Wenzhou Medical University in Zhejiang, China discusses the potential of a new cancer immunotherapy approach. The researchers focused on the interaction between T-cell receptors and peptide-MHC-I complexes on cancer cell membranes, which is crucial for the effectiveness of T-cell-based cancer immunotherapies. They developed a strategy using self-assembling peptides to generate light-activatable supramolecular antigens on tumor cells, allowing for precise control of antigen presentation. The researchers found that this approach could broaden the repertoire of tumor antigens for T-cell immunotherapies and improve their precision and effectiveness. [Extracted from the article]

Researchers at Zhejiang University in China have conducted a study on the impact of protein corona and pegylation on the accumulation and efficacy of lysosome-disrupting lipid nanoparticles in Kras-mutated cancer. The study found that protein corona facilitated targeted delivery of the nanoparticles to Kras-mutated cancer cells, while pegylation hindered delivery and efficacy. The researchers also discovered that the nanoparticles sensitized immunosuppressive Kras-mutated cancers to anti-PD1 immunotherapy. These findings suggest that the context-dependent role of the protein corona should be considered when designing nanoparticle-based drug delivery systems, and that PEGylation may not be suitable for all cancer types. [Extracted from the article]

A study conducted by researchers at Wenzhou Medical University in Zhejiang, China, explores the role of exosomes and long non-coding RNAs (lncRNAs) in clear cell renal cell carcinoma (ccRCC). The researchers constructed an exosome-related lncRNA score and a ceRNA network to predict the response to immunotherapy and potential targeted drugs in ccRCC. They identified a score consisting of four exosome-related lncRNAs that could be considered a risk factor for prognosis in ccRCC patients. The study also identified the EMX2OS/hsa-miR-31-5p/TLN2 axis as a potential therapeutic target for ccRCC. [Extracted from the article]

Researchers from Zhejiang University in China have developed a new method to enhance anticancer immunity. The researchers created a syringeable, near-infrared light-activated hydrogel that can be implanted near tumors. When the hydrogel is exposed to near-infrared laser irradiation, it triggers the release of encapsulated agents and induces immunogenic cell death in cancer cells, leading to improved immunotherapeutic efficacy. The hydrogel has shown promising results in preclinical models of melanoma and triple-negative breast cancer, which are typically resistant to conventional immunotherapy. This research provides a locally administrable approach to stimulate systemic immunity and improve cancer treatment outcomes. [Extracted from the article]

A report from Zhejiang University in China discusses research on the treatment of colorectal cancer using immune checkpoint inhibitors (ICIs). The majority of colorectal cancers are insensitive to ICIs due to fewer tumor antigens. The researchers hypothesized that intratumoral injection of interferon gamma (IFN gamma) followed by PD1 blockade could boost antitumor immunity. Their preclinical data showed that a combined treatment strategy using IFN gamma and anti-PD-1 antibody increased T cell killing of tumor cells and inhibited tumor growth in a mouse model of colorectal cancer. [Extracted from the article]

A recent study conducted at Zhejiang University in China has developed a novel tri-specific T cell engager called DR30318 for the immunotherapy of cancers that express Claudin 18.2 (CLDN18.2). The antibody demonstrated binding affinity to CLDN18.2, human serum albumin (HSA), and CD3, and showed T cell-dependent cellular cytotoxicity (TDCC) activity in vitro. In animal models, DR30318 exhibited significant tumor suppression effects on gastric and pancreatic cancer xenografts without affecting body weight. This research provides promising insights into the development of targeted immunotherapies for solid tumors. [Extracted from the article]

A meta-analysis of randomized controlled trials conducted by researchers at Taizhou University in Zhejiang, China, evaluated the effects of immunomodulatory drugs on immune and cardiac function in patients with heart failure. The study found that immunomodulatory drugs can safely improve cardiac function, motor function, immune function, and quality of life in patients with heart failure. The analysis included 11 studies and found that patients treated with immunomodulatory drugs had significantly lower left ventricular end-diastolic dimension, left ventricular end-systolic diameter, high sensitivity C reactive protein, brain natriuretic peptide, tumor necrosis factor-alpha, interleukin-6, interleukin-1 beta, and quality of life scores compared to the control group. However, left ventricular ejection fraction and 6-minute walking distance were higher in the immunomodulatory drug group. There were no significant differences in interleukin-10 levels or adverse events between the two groups. [Extracted from the article]

Researchers from Wenzhou Medical University in Zhejiang, China have developed an artificial membrane disruptor (AMD) that can induce plasma membrane rupture (PMR) in pyroptosis-deficient tumor cells. The AMDs, which are micron-scale Ce6-based particles, specifically target the plasma membrane and can mediate fast and irreversible PMR under red light. In preclinical studies, the AMDs demonstrated the ability to induce programmed cell death and lytic cell death, resulting in efficient tumor elimination with minimal damage to major organs. The study provides new insights into the design of bioinspired membrane disruptors for PMR and anti-tumor immunotherapy. [Extracted from the article]

A study conducted in Zhejiang, China, aimed to investigate the comprehensive needs of lung cancer patients treated with immune checkpoint inhibitors and explore the relationships between these needs, social support, and disease perception. The study found that the highest level of comprehensive needs was in the domain of "medical demand," with the need for information about financial support being the highest. The research also identified significant correlations between comprehensive needs, social support, and disease perception. Factors such as immunotherapy course, occurrence of immune-related adverse events, disease perception, and social support were found to influence patients' comprehensive needs. The study suggests the importance of providing individualized supportive care to lung cancer patients during their treatment. [Extracted from the article]

A report from Zhejiang University in China discusses the mechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity. T cells play a crucial role in adaptive immunity, providing protection against diseases and maintaining immunological balance. The researchers explore the migratory modes and positioning of T cells in different tissues and organs, as well as the pharmacological modulation of their chemotaxis. They also review clinical applications of antigen-reactive or antigen-tolerogenic T cells for various disorders. The study suggests potential future developments in immunotherapies for cancer and autoimmune diseases by regulating T cell migratory patterns. [Extracted from the article]

Researchers at Zhejiang University in China have developed a new nanoplatform for the treatment of hepatocellular carcinoma (HCC), a type of liver cancer. The nanoplatform, called CTEP, combines photodynamic therapy (PDT) with immunotherapy to improve the effectiveness of treatment. CTEP utilizes acid-etched layered double hydroxides nanosheets armed with dual "doorkeepers" to target HCC cells and induce pyroptosis, a form of cell death that stimulates the immune system. The combination of PDT and immunotherapy through pyroptosis shows promise as a smart strategy for HCC treatment. [Extracted from the article]

A study conducted at Zhejiang University in China explored the role of CD24(hi)CD27(+) regulatory B cells (Bregs) in promoting drug resistance in breast cancer cells within metastatic lymph nodes (mLNs). The researchers collected mLNs samples from breast cancer patients who had received neoadjuvant therapy and analyzed the spatial features of CD24(hi)CD27(+) Bregs. They found a close spatial correlation between activated Bregs and residual tumor cells within mLNs. Mechanistically, Bregs enhanced the acquisition of multidrug resistance and stem-like features in breast cancer cells by secreting IL6 and TNF alpha. The study suggests that targeting Bregs and blocking their interactions with breast cancer cells could improve tumor regression in mLNs and provide a novel strategy for chemoimmunotherapy combination in breast cancer patients with mLNs. [Extracted from the article]

A recent study conducted by researchers at the School of Medicine in Zhejiang, China, has explored the correlation between serine and glycine metabolism-related genes (SGMGs) and the prognosis and tumor immune microenvironment (TIME) of hepatocellular carcinoma (HCC), a type of liver cancer. The study identified two distinct subtypes of HCC and constructed a risk score prognostic model based on SGMGs. Patients with a higher risk score showed a poor prognosis, and there were significant differences in immune cell infiltration between high- and low-risk groups. The study provides valuable insights for predicting the prognosis and developing treatment strategies for HCC patients. [Extracted from the article]

A case report from Zhejiang University in the People's Republic of China discusses a rare thoracic malignancy called pulmonary blastoma. The report describes the case of a 67-year-old man who was incidentally found to have a lung nodule during a chest CT examination. The patient did not receive any treatment initially but later presented with chest pain. A biopsy confirmed the diagnosis of pulmonary blastoma. The report includes images of the tumor before and after chemotherapy and immunotherapy, which is a novel finding. This research has been peer-reviewed and provides valuable insights into this rare form of cancer. [Extracted from the article]

A recent study conducted by researchers at Zhejiang University in China has developed and validated a prognostic signature for colon adenocarcinoma (COAD) based on the expression of 12 immune- and cancer-associated fibroblast-related genes. The signature was found to have a higher C-index than previous COAD signatures, indicating its robustness and reliability. Additionally, a nomogram was developed to incorporate the signature and key clinical parameters for use in clinical settings. The study also explored the relationship between the signature and other immunotherapy variables, leading to more precise prediction of treatment efficacy and personalized immunotherapy for COAD patients. [Extracted from the article]

A recent study conducted by researchers from Zhejiang University in China has explored the potential of gasdermin-mediated pyroptosis in conferring anticancer immunity. Pyroptosis is a form of immunogenic cell death that has shown promise in eradicating cancer cells and promoting immune cell activation in the tumor microenvironment. The researchers used a bispecific antibody to trigger pyroptosis in gastric cancer cells, leading to improved tumor cell eradication. This innovative strategy could potentially enhance the effectiveness of cancer immunotherapy. The study highlights the challenges and future directions of employing pyroptosis in cancer treatment. [Extracted from the article]

A recent study conducted by researchers at Ningbo University in Zhejiang, China, has found that Synaptopodin 2 (SYNPO2) plays a significant role in the growth and progression of bladder urothelial carcinoma (BLCA). The study utilized BLCA RNA sequencing data and found that elevated SYNPO2 expression was associated with poor survival outcomes. The researchers also discovered that increased SYNPO2 levels led to increased infiltration of mast cells in BLCA tissue, which in turn exacerbated resistance to immune therapy and conventional chemotherapy. These findings suggest that SYNPO2 may serve as a promising prognostic factor in BLCA. [Extracted from the article]

A recent study conducted by researchers at Wenzhou Medical University in Zhejiang, China, explores the potential of using ultralow-dose chemical drugs to induce pyroptosis, a form of cell death, as a means of enhancing antitumor immune function. The study establishes a near-infrared light controllable killing system that effectively transports ultralow-dose doxorubicin to tumor cells, resulting in efficient pyroptosis. The researchers found that this system demonstrated good tumor targeting and penetration, and that ultralow-dose chemotherapy was sufficient for inducing a robust pyroptosis-mediated antitumor immunity. This research provides new insights into the design of nanoassisted systems for activating antitumor immunity and suggests the potential of ultralow-dose chemotherapy in antitumor therapies. [Extracted from the article]

A recent study conducted at Zhejiang University in China has explored the potential of using metformin, a widely used clinical drug, to induce pyroptosis in tumors. Pyroptosis is a form of cell death that releases inflammatory substances and improves tumor immunogenicity. The researchers developed a pH-responsive nanocarrier that can deliver metformin and an anti-PD-1 monoclonal antibody for cancer immunotherapy. The nanocarrier showed promising results in promoting tumor immunity and improving therapeutic outcomes. This research provides valuable insights into the development of novel approaches for tumor immunotherapy. [Extracted from the article]

A report from Zhejiang University in China discusses the management of locally advanced non-small cell lung cancer (LA-NSCLC). The researchers highlight the challenges and limitations of traditional therapeutic strategies and explore the potential of targeted therapies, immunotherapies, and novel radiotherapies in treating LA-NSCLC. They also discuss the use of adjuvant, neoadjuvant, and perioperative targeted and immune strategies in patients with resectable LA-NSCLC, as well as combinations of chemoradiation and immunotherapy/targeted therapy in unresectable cases. The report aims to provide insights into optimizing clinical management and improving the cure rate of LA-NSCLC. [Extracted from the article]